ClinicalTrials.gg
DrugRead study by study

Palbociclib clinical trials

Also written Ibrance, PD-0332991 and PD 332991.

studies test it
225
open now
47
in phase 3
23
first study started
2004
ClinicalTrials.gov finds 443 studies for palbociclib. How that becomes 225 here

Every study that search finds has been read, apart from the 3 newest, to see whether and how it gives palbociclib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count

  1. 443Found by its intervention search · See all 443 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 375 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −6
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −1New since the last reading, not read yet
  4. 436Give palbociclib to participants
  5. −73Observe patients on it, or give it outside a trial
  6. −7Compare another treatment with it
  7. −131Give it beside what is tested
  8. 225Test it: the count on this site

Get an email when these change. Save the palbociclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
3 Feb 2015 · IBRANCE · NDA 207103 (FDA, Drugs@FDA)
European Union
9 Nov 2016 · Ibrance · EMEA/H/C/003853 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Palbociclib
142
6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one
16
Palbociclib 125mg
13
Palbociclib, PD-0332991
5
Palbociclib alone
4

Brand

Ibrance
92

Development codes

PD-0332991
58
PD 332991
19
PD 991
15
PD 0332991-00
2

In one entry with another drug

Given together, or one or the other

Palbociclib + Rabeprazole
2

Studies by the year they started

225 studies that test it; most in 2017 (27)

Studies that test palbociclib, by start year
YearStudies
20041
20071
20082
20091
20103
20115
20125
201313
201421
201522
201617
201727
201821
201917
20208
20219
202213
202311
202417
20259
20262

Who runs them

Industry 43 · Other 182

Pfizer (35) · National Cancer Institute (NCI) (9) · Washington University School of Medicine (6) · Dana-Farber Cancer Institute (6) · Abramson Cancer Center at Penn Medicine (4) · Georgetown University (4) · Alliance Foundation Trials, LLC. (3) · M.D. Anderson Cancer Center (3)

Often tested with

Tested in the same studies.

Ribociclib (15) · Letrozole (14) · Olaparib (13) · Trastuzumab (10) · Pertuzumab (8) · Binimetinib (7) · Crizotinib (7) · Fulvestrant (7)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Palbociclib is the comparator. A study of two new drugs counts under both.

  • 1Atirmociclib · Pfizer · next primary completion Jan 2029
  • 1HRS-6209 · Jiangsu HengRui Medicine Co., Ltd. · next primary completion Jul 2031
  • 1CDK4 Inhibitor BGB-43395 · BeOne Medicines · next primary completion Apr 2029
New treatments tested with it · 8 most studied

New when their studies opened, with palbociclib beside them; studies of each.

Reaching primary completion within a year · 21, 1 in phase 3

Studies that test palbociclib, phase 3 first.

Studies

Open first, then newest update. How each study uses palbociclib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 225

See all 225 studies that test palbociclib →

Behind its US label · 2 — the studies the FDA label of IBRANCE describes

From the Clinical Studies section of IBRANCE (2026-07), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 42 — no other medicine in its arm

Showing 20 of 42. See all 42 →

Tested with established drugs · 58 — they are given beside it

Showing 20 of 58. See all 58 →

Tested in a combination · 125 — another drug in the study is under test too

Showing 20 of 125. See all 125 →

Beside an established treatment under test · 20 — an approved drug, surgery or radiation is what the study tests

Tested with palbociclib: Radiation 4 · Surgery or a procedure 3 · Fulvestrant 3 · cemiplimab 1 · pembrolizumab 1 · Hydroxychloroquine 1 · Letrozole 1 · Tamoxifen 1

Beside a new treatment under test · 87 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with palbociclib: giredestrant 6 · ipatasertib 6 · AZD9833 5 · inavolisib 5 · gedatolisib 5 · pyrotinib 3 · capivasertib 2 · vepdegestrant 2

Showing 20 of 87. See all 87 →

Beside supportive care · 14 — a supportive treatment or test is studied
One option of several · 10 — a test or a strategy chooses among drugs
As the comparator · 7 — what is tested is compared with palbociclib
Observed · 73 — patients on it are followed, or it is given outside a trial

Showing 20 of 73. See all 73 →

Codes

What other systems call palbociclib · ClinicalTrials.gg INT004770

  • MeSH (NLM) C500026palbociclibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) G9ZF61LE7GPALBOCICLIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1601374Confirmed FDA, Wikidata
  • Wikidata Q15269707palbociclibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C49176PalbociclibOne source FDA
  • DrugBank DB09073One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion